Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver disease.

Cherniavskyi V, Akimov A, Parunian L, Tishchenko V, Seredenko A

Wiadomosci lekarskie (Warsaw, Poland : 1960)1 Jan 2026

PMID42139606DOI10.36740/wlek/216930PepBankPUB-42139606

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved total cholesterol more than lifestyle-only control and dapagliflozin.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved total cholesterol more than lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
Direction not reportedTotal cholesterol
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Lipids · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960601
02HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved LDL cholesterol more than lifestyle-only control and dapagliflozin.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved LDL cholesterol more than lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
Direction not reportedLow-density lipoprotein cholesterol
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Lipids · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960602
03HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved triglycerides more than lifestyle-only control and dapagliflozin.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved triglycerides more than lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
Direction not reportedTriglycerides
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Lipids · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960603
04HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved HDL cholesterol more than lifestyle-only control and dapagliflozin.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, liraglutide improved HDL cholesterol more than lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
Direction not reportedHigh-density lipoprotein cholesterol
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Lipids · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960604
05HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, Globorisk cardiovascular risk scores decreased in all groups without differences between liraglutide, lifestyle-only control and dapagliflozin.
In plain wordsIn adults with MASLD, Globorisk risk scores fell in all groups, without differences between liraglutide, lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant changeGloborisk cardiovascular risk score
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960605
06HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, Framingham Risk Scores decreased in all groups without differences between liraglutide, lifestyle-only control and dapagliflozin.
In plain wordsIn adults with MASLD, Framingham risk scores fell in all groups, without differences between liraglutide, lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant changeFramingham Risk Score
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960612
07HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, ACC/AHA ASCVD Risk Calculator scores decreased in all groups without differences between liraglutide, lifestyle-only control and dapagliflozin.
In plain wordsIn adults with MASLD, ACC/AHA ASCVD risk scores fell in all groups, without differences between liraglutide, lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant changeACC/AHA ASCVD Risk Calculator score
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960614
08HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, Prospective Cardiovascular Munster Scores decreased in all groups without differences between liraglutide, lifestyle-only control and dapagliflozin.
In plain wordsIn adults with MASLD, Munster risk scores fell in all groups, without differences between liraglutide, lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant changeProspective Cardiovascular Munster Score
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960616
09HumanRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, World Health Organization cardiovascular risk chart scores decreased in all groups without differences between liraglutide, lifestyle-only control and dapagliflozin.
In plain wordsIn adults with MASLD, WHO risk scores fell in all groups, without differences between liraglutide, lifestyle-only control and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant changeWorld Health Organization cardiovascular risk chart score
Study
n = 115
Comparator
Lifestyle-only control and dapagliflozin
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960618
10HumanRandomized controlled trialEfficacy outcome
In 38 adults with metabolic dysfunction-associated steatotic liver disease receiving liraglutide, NT-proBNP increased from baseline to six months; it also increased in the lifestyle-only control group.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease receiving liraglutide, NT-proBNP increased from baseline; it also increased in lifestyle-only controls.
Peptide
Liraglutide
Outcome
IncreaseN-terminal pro-B-type natriuretic peptide
Study
n = 38
Outcome group
Heart function · Cardiovascular
Studied dose
titrated to 1.8 milligrams daily · six monthsAs given in this study (human).
Source sentences
Summary
N-terminal pro-B-type natriuretic peptide levels increased significantly in the control and liraglutide groups, but remained unchanged in the dapagliflozin group.
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
Report a problemFND-4213960606

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, total cholesterol improved within all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, total cholesterol improved in every group, including control.
Peptide
Liraglutide
Outcome
Direction not reportedTotal cholesterol within-group improvement
Study
n = 115
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960607
12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, low-density lipoprotein cholesterol improved within all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, LDL cholesterol improved in every group, including control.
Peptide
Liraglutide
Outcome
Direction not reportedLow-density lipoprotein cholesterol within-group improvement
Study
n = 115
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960608
13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, triglycerides improved within all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, triglycerides improved in every group, including control.
Peptide
Liraglutide
Outcome
Direction not reportedTriglycerides within-group improvement
Study
n = 115
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960609
14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, high-density lipoprotein cholesterol improved within all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, HDL cholesterol improved in every group, including control.
Peptide
Liraglutide
Outcome
Direction not reportedHigh-density lipoprotein cholesterol within-group improvement
Study
n = 115
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
All groups showed significant within-group improvements in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (p < 0.001), with liraglutide showing greater lipid improvements intergroup (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960610
15HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, Globorisk cardiovascular risk scores decreased in all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, Globorisk risk scores decreased in all groups, including lifestyle-only control.
Peptide
Liraglutide
Outcome
DecreaseGloborisk cardiovascular risk score within-group change
Study
n = 115
Outcome group
Cardiometabolic risk factors · Cardiovascular
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960611
16HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, Framingham Risk Scores decreased in all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, Framingham risk scores decreased in all groups, including lifestyle-only control.
Peptide
Liraglutide
Outcome
DecreaseFramingham Risk Score within-group change
Study
n = 115
Outcome group
Cardiometabolic risk factors · Cardiovascular
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960613
17HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, ACC/AHA ASCVD Risk Calculator scores decreased in all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, ACC/AHA ASCVD risk scores decreased in all groups, including lifestyle-only control.
Peptide
Liraglutide
Outcome
DecreaseACC/AHA ASCVD Risk Calculator score within-group change
Study
n = 115
Outcome group
Cardiometabolic risk factors · Cardiovascular
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960615
18HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, Prospective Cardiovascular Munster Scores decreased in all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, Munster risk scores decreased in all groups, including lifestyle-only control.
Peptide
Liraglutide
Outcome
DecreaseProspective Cardiovascular Munster Score within-group change
Study
n = 115
Outcome group
Cardiometabolic risk factors · Cardiovascular
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960617
19HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with metabolic dysfunction-associated steatotic liver disease, World Health Organization cardiovascular risk chart scores decreased in all groups, including lifestyle-only control.
In plain wordsIn adults with metabolic dysfunction-associated steatotic liver disease, WHO risk scores decreased in all groups, including lifestyle-only control.
Peptide
Liraglutide
Outcome
DecreaseWorld Health Organization cardiovascular risk chart score within-group change
Study
n = 115
Outcome group
Cardiometabolic risk factors · Cardiovascular
Source sentences
Summary
Cardiovascular risk scores decreased significantly in all groups, with no differences between them.
4 context sentences(design, population, supporting numbers)
Summary · context
Cardiovascular risk was assessed using five validated scales: Globorisk, Framingham Risk Score, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease Risk Calculator, Prospective Cardiovascular Munster Score, and World Health Organization cardiovascular risk charts.
Summary · context
This prospective, randomized, parallel-group study included 115 adult patients with metabolic dysfunction-associated steatotic liver disease. Participants were randomized into three groups: control (n = 36, lifestyle intervention only), dapagliflozin (n = 41, 10 milligrams daily), or liraglutide (n…
Summary · context
All patients adhered to a Mediterranean diet and moderate physical activity.
Summary · context
Lipid profile and N-terminal pro-B-type natriuretic peptide levels were measured at baseline and six months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4213960619

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.